Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
Animals
Antibodies, Monoclonal
/ pharmacology
Antibody-Dependent Cell Cytotoxicity
CHO Cells
Carcinoma, Squamous Cell
/ drug therapy
Cell Line, Tumor
Cricetinae
Cricetulus
Dog Diseases
/ drug therapy
Dogs
Endothelial Cells
/ drug effects
Heterografts
Humans
Immunoconjugates
/ pharmacology
Melanoma
/ drug therapy
Membrane Glycoproteins
/ genetics
Mice
antibody–drug conjugate
dog podoplanin
monoclonal antibody
Journal
Monoclonal antibodies in immunodiagnosis and immunotherapy
ISSN: 2167-9436
Titre abrégé: Monoclon Antib Immunodiagn Immunother
Pays: United States
ID NLM: 101590955
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
18
3
2020
medline:
27
1
2021
entrez:
18
3
2020
Statut:
ppublish
Résumé
Antibody-drug conjugates (ADCs), which consist of a monoclonal antibody (mAb), a linker, and a payload, can deliver a drug to cancer tissues. We previously produced an anti-dog podoplanin (dPDPN) mAb, PMab-38, which reacts with dPDPN-expressing canine melanomas and squamous cell carcinomas (SCCs), but not with dPDPN-expressing canine type I alveolar cells or lymphatic endothelial cells, indicating that PMab-38 possesses cancer specificity. In this study, we developed an ADC, P38B-DM1, using the mouse-canine chimeric anti-dPDPN antibody, P38B as the antibody, a peptide linker, and emtansine as the payload using the chemical conjugation by affinity peptide (CCAP) method. We investigated its cytotoxicity against dPDPN-overexpressed Chinese hamster ovary (CHO/dPDPN) cells
Identifiants
pubmed: 32182186
doi: 10.1089/mab.2020.0001
pmc: PMC7185362
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunoconjugates
0
Membrane Glycoproteins
0
PDPN protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-44Références
Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):218-223
pubmed: 30362926
Oncotarget. 2015 Nov 3;6(34):36003-18
pubmed: 26416352
Monoclon Antib Immunodiagn Immunother. 2017 Apr;36(2):68-71
pubmed: 28339303
Acta Neuropathol. 2006 May;111(5):483-8
pubmed: 16596424
Oral Oncol. 2018 Mar;78:126-136
pubmed: 29496040
Sci Rep. 2014 Aug 01;4:5924
pubmed: 25080943
Chembiochem. 2019 Nov 4;20(21):2729-2737
pubmed: 30973187
Pathol Int. 2005 Feb;55(2):83-6
pubmed: 15693854
Tumour Biol. 2005 Jul-Aug;26(4):195-200
pubmed: 16006773
Monoclon Antib Immunodiagn Immunother. 2017 Dec;36(6):291-295
pubmed: 29161183
Vet Immunol Immunopathol. 2014 Jan 15;157(1-2):31-41
pubmed: 24268690
Monoclon Antib Immunodiagn Immunother. 2016 Dec;35(6):293-299
pubmed: 27801621
J Biol Chem. 1995 Jul 28;270(30):17815-22
pubmed: 7629082
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5688-92
pubmed: 8650153
Monoclon Antib Immunodiagn Immunother. 2016 Dec;35(6):304-306
pubmed: 27918691
Protein Expr Purif. 2014 Mar;95:240-7
pubmed: 24480187
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
J Immunol. 2013 Jun 15;190(12):6239-49
pubmed: 23690472
Monoclon Antib Immunodiagn Immunother. 2016 Aug;35(4):212-6
pubmed: 27380308
Biochem Biophys Rep. 2018 Nov 24;17:23-26
pubmed: 30519645
Monoclon Antib Immunodiagn Immunother. 2016 Oct;35(5):263-266
pubmed: 27788030
Am J Pathol. 1997 Oct;151(4):1141-52
pubmed: 9327748
Bioconjug Chem. 2019 Mar 20;30(3):698-702
pubmed: 30606013
Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597
pubmed: 30854738